Gallic Acid Blocks Prostate Cancer Progression by Disrupting a Key Molecular Switch

Prostate cancer remains one of the most formidable health challenges facing men worldwide, ranking as the second most commonly diagnosed malignancy in the male population. For decades, the cornerstone of advanced disease management has been androgen-deprivation therapy, a strategy that starves prostate tumors of the hormones they depend upon for growth. Yet while this approach often produces dramatic initial responses, a substantial proportion of patients inevitably progress to a far more aggressive and treatment-resistant stage known as castration-resistant prostate cancer. At this point, the therapeutic options narrow considerably, and the outlook for many patients darkens. The molecular machinery that drives this transition has proven extraordinarily complex, involving cascades of transcription factors, signaling pathways, and cell-surface molecules that conspire to make tumor cells more invasive, more resilient, and harder to eliminate. It is precisely this complexity that has pushed researchers to search for new molecular targets whose manipulation could halt disease progression safely and effectively.

Now, a research team led by Professor Jun Zhang from the Shihezi University School of Medicine in China, together with Professor Jingzhou Wang and Dr. Cuizhe Wang from Shihezi University, has reported findings that may reshape how scientists think about intercepting advanced prostate cancer. Their study, published in the Chinese Medical Journal and made available online on July 15, 2026, centers on a transcription factor called Krüppel-like factor 7, or KLF7, a protein that binds to DNA and regulates the expression of downstream genes. Using RNA sequencing and bioinformatics analysis of prostate cancer samples, the team discovered that KLF7 is highly expressed in prostate tumors, where it acts as a direct transcriptional activator of L1 cell adhesion molecule, known as L1CAM. This cell-surface protein has long been associated with tumor metastasis, the process by which cancer cells detach from the primary tumor, invade surrounding tissues, and colonize distant organs. By linking KLF7 to L1CAM expression, the researchers identified a previously underappreciated route through which prostate cancer cells acquire their malignant properties.

The significance of the finding deepened when the investigators traced the regulatory chain one step further upstream. Above KLF7 in the signaling hierarchy sits nuclear factor kappa B, or NF-κB, a master transcriptional regulator famous for its roles in inflammation, immunity, and cancer. Specifically, the study demonstrated that the phosphorylation of the NF-κB p65 subunit serves as the master regulator of the entire KLF7/L1CAM axis. When p65 is phosphorylated, it becomes transcriptionally active, driving KLF7 expression, which in turn switches on L1CAM and promotes the aggressive behaviors that characterize advanced prostate cancer. This three-component pathway, the NF-κB/KLF7/L1CAM axis, therefore represents a linear signaling circuit in which a single upstream event, the phosphorylation of p65, can unleash a cascade of pro-tumor effects. Interrupting that circuit at its origin could, in principle, suppress the entire malignant program with a single intervention.

That is exactly where gallic acid enters the story. Gallic acid is a naturally occurring phenolic compound found in gallnuts, tea leaves, grapes, and a variety of other plant sources, and it has attracted growing attention for its anti-inflammatory and anti-cancer properties. What remained unclear until now was the precise molecular mechanism by which it might act against prostate cancer. To resolve this question, the research team turned to two complementary structural and biophysical techniques: surface plasmon resonance and molecular docking. Surface plasmon resonance is a label-free optical method that measures real-time binding between molecules, allowing researchers to confirm whether a small molecule physically attaches to a target protein and how stable that interaction is. Molecular docking, by contrast, uses computational modeling to predict exactly where and how a ligand fits into the three-dimensional structure of its protein target.

Using these approaches, the researchers confirmed that gallic acid forms a stable complex with the NF-κB p65 subunit, and they pinpointed the interaction with remarkable precision: the compound specifically targets the serine 276 phosphorylation site of p65. This site is a critical regulatory node, because phosphorylation at serine 276 is one of the key modifications that activates p65 as a transcription factor. By occupying or otherwise interfering with this site, gallic acid prevents the phosphorylation event from occurring, effectively locking p65 in an inactive state. The downstream consequences are exactly what the signaling model predicts: with p65 silenced, KLF7 is not activated, L1CAM is not expressed, and the pro-metastatic program that depends on this axis is shut down. In effect, gallic acid functions as a molecular circuit breaker, cutting the power to the entire pathway at its source rather than trying to suppress each downstream effect individually.

The team then moved from structural biology to functional validation, testing whether this mechanism translates into meaningful effects against actual prostate cancer cells. In laboratory culture experiments, gallic acid significantly impaired the aggressive behaviors of two widely used prostate cancer cell lines, PC-3 and LNCaP. These cell lines are standard models in prostate cancer research, with PC-3 representing a highly invasive, androgen-independent phenotype and LNCaP representing an androgen-sensitive one, so activity against both suggests the compound’s mechanism operates independently of androgen signaling status. Equally important was what the researchers did not observe: gallic acid exhibited no toxicity toward normal prostate stromal cells, the healthy supporting tissue of the prostate. This selectivity profile is a critical consideration for any potential therapeutic, because many conventional cancer drugs inflict collateral damage on healthy tissue, producing the debilitating side effects that limit treatment intensity and patient quality of life.

To determine whether these cellular findings could withstand the far more demanding environment of a living organism, the researchers conducted experiments in a high-fat-diet-induced obesity mouse model. This model choice is scientifically deliberate rather than incidental. Obesity is a well-established risk factor for more aggressive prostate cancer, and the metabolic and inflammatory conditions it creates are known to activate NF-κB signaling, making it a clinically relevant setting in which to test a compound that targets this pathway. In these animals, administration of gallic acid significantly reduced both tumor volume and tumor weight, demonstrating that the compound’s anti-cancer effects extend beyond the controlled conditions of a cell culture dish into the complex biology of a whole organism.

Perhaps the most striking result of the in vivo work was the comparison with established drugs. The anti-tumor efficacy of gallic acid proved comparable to that of conventional therapeutics such as enzalutamide and bicalutamide, both of which are androgen receptor signaling inhibitors used in the clinic for advanced prostate cancer. Even more encouraging, combination therapy pairing gallic acid with these conventional agents produced enhanced therapeutic outcomes, suggesting that the natural compound could complement existing treatments rather than merely duplicating them. This kind of synergy is highly sought after in oncology, because combination regimens can improve efficacy while potentially allowing lower doses of each individual drug, thereby reducing toxicity. For patients whose tumors have progressed beyond the reach of hormone therapy alone, a well-tolerated natural product that sensitizes tumors to standard drugs could represent a meaningful addition to the therapeutic arsenal.

The implications of the study extend beyond prostate cancer itself. The NF-κB pathway is a central hub in the biology of inflammation and cancer more broadly, and KLF7 and L1CAM have been implicated in other malignancies as well. A validated strategy for disabling the NF-κB/KLF7/L1CAM axis through a small, naturally derived molecule could therefore inform therapeutic development in multiple cancer types. Moreover, the study exemplifies a modern, mechanism-first approach to drug repurposing: rather than simply observing that a compound has anti-cancer effects, the researchers identified the exact molecular target, the exact binding site, and the exact signaling consequences, building a complete mechanistic chain from molecule to phenotype. As the authors and their supporters, including funding from the Tianshan Talent Project in Xinjiang Autonomous Region and the Scientific and Technological Research Project of Xinjiang Production and Construction Corps, look toward future work, the study provides what the team describes as a strong theoretical basis for the clinical application of gallic acid as a safe and potent agent against advanced prostate cancer. Translating these findings into human therapies will require further preclinical development and eventually clinical trials, but the foundation has been laid: a common plant compound, a precisely defined molecular target, and a signaling axis whose disruption strikes at the heart of what makes advanced prostate cancer lethal.

Subject of Research: Inhibition of the NF-κB/KLF7/L1CAM signaling axis by gallic acid as a therapeutic mechanism against prostate cancer progression

Article Title: Chinese Medical Journal study reveals gallic acid inhibits prostate cancer progression via the NF-κB/KLF7/L1CAM Axis

Article References: Chinese Medical Journal study reveals gallic acid inhibits prostate cancer progression via the NF-κB/KLF7/L1CAM Axis. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: prostate cancer, gallic acid, NF-κB p65, KLF7, L1CAM, castration-resistant prostate cancer, transcription factor, surface plasmon resonance, molecular docking, enzalutamide, bicalutamide, natural compounds